Netflix and Allergan Lead the Way

 | Apr 22, 2014 | 11:27 AM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

nflx

,

agn

,

feye

,

yelp

,

expe

,

pcln

,

biib

,

celg

All the bulls need is leadership. Netflix (NFLX) and Allergan (AGN) can provide that leadership.

First, we see many Internet companies going higher, and that's because Netflix blew the numbers away. What does Netflix have to do with these stocks? Quite simply, they trade as a cohort. They are all stocks with huge growth rates, of companies that spend like mad to take share of their markets. They are all companies that have opportunities that are too big to rein in spending.

In that sense, Yelp (YELP), Expedia (EXPE), Priceline (PCLN) and TripAdvisor (TRIP) can't be kept down if Netflix goes higher, because the shorts, who have been weighing on them, now fear upside surprises. These had seemed like risk-free annuities until today.

These stocks are also getting a boost from an unlikely corner: FireEye (FEYE). This Internet security company has been on a one-way ticket down from $96, a victim of overvaluation and then massive insider selling, including 14 million shares priced at $82.

This morning, shareholders of Mandiant, who got FireEye stock when FireEye acquired Mandiant in January, filed 13.3 million shares, and the stock is higher. I have been waiting for the insider selling to stop. But maybe the fact that insiders are selling at 50% below the peak is a sign that there could be a bargain afoot. I am adamant that the coming Airbnb, Dropbox and Box IPOs will hurt the group again, but it is an encouraging sign that FireEye isn't breaking down.

Finally, Allergan makes the shorts feel uncertain about going up endlessly against Celgene (CELG), Biogen Idec (BIIB), Regeneron (REGN) and Gilead (GILD), as well as Jazz Pharma (JAZZ) and Isis (JAZZ), which have also been free-fire zones for short-sellers.

If big pharma is taking action and waking up from its slumber and there's money being tossed around among Eli Lilly (LLY), GlaxoSmithKline (GSK), Novartis (NVS) and potentially Pfizer (PFE)-Astra Zeneca (AZN), then you can't be big short these stocks without worry anymore.

Now it doesn't hurt that once again we have earnings per share that show real sales growth: Halliburton (HAL), Netflix and today United Technologies (UTX). Nor does it hurt that analysts such as Morgan Stanley's software-as-a-service guy say it is time to buy the cloud group -- although Medidata (MDSO) sure made that call suspect.

Nor does it hurt that Credit Suisse pulled the trigger on an upgrade for Facebook (FB) the day before it reports. That's either gutsy or suicidal -- I don't know which ... yet.

Still, what matters is the end -- at least momentarily -- of the short tyranny that had mired super-high-growth stocks and left them like easily harpooned, beached-up whales.

Now, if we actually get some good numbers from these Internet companies that "look" like Netflix, and from the biotechs that "resemble" Allergan, then the rally can continue. 

Columnist Conversations

The bearish star cluster on the Starbucks (SBUX) chart that I highlighted last week preceded price action this...
Ford is working on its third straight gain following two days of steep loses to start this week. At this...
Market is holding on for gains for now but think Doug Kass is right and could see some decent profit taking by...
I have a full blown article surrounding the U.S. Retail Sector coming out on soon, but for now let's just lo...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.